Study on Evaluvation of Benzo (a) Pyrene Soluble Fraction in Respirable Suspended Particulate Matter in Peenya Industrial Area by GCMS

Abstract Polycyclic aro matic hydrocarbons (PAHs) were identified to be one of the major to xic air pollutants in urban environment. PA Hs are mostly formed during incomp lete combustion or pyrolysis of organic material. According to National ambient air quality Indian standard, benzo (a) pyrene (BaP) concentration Part iculate matter (PM 10 ) in amb ient air in the Peenya industrial area Bangalore met ropolitan in India has been determined. Air samp les for the analysis of BaP in suspended particles have been collected (as 24 h sample once in a month) at selected monitoring sites within the Peenya industrial monitoring network. In this research work, the results of PM 10 were collected between February 2011 and April 2011. The Ben zo(a)pyrene concentrations of the eight sampling sites ranged fro m zero to 0.0490ng/ m 3 . Spatial variations were predo minantly due to the different strengths of source emission. The total Benzo (a)pyrene concentrations at Kongovi Monitoring Station site was higher than those at other seven sites during monitoring period, observing the results obtained during the period of a whole year, it was concluded that, the concentrations of BaP were much h igher during winter season at almost all measuring sites

Patient perspectives on digital healthcare technology in care and clinical trials for motor neuron disease : an international survey

Introduction To capture the patient’s attitude toward remote monitoring of motor neuron disease (MND) in care and clinical trials, and their concerns and preferences regarding the use of digital technology. Methods We performed an international multi-centre survey study in three MND clinics in The Netherlands, the United Kingdom, and Australia. The survey was co-developed by investigators and patients with MND, and sent to patients by e-mail or postal-mail. The main topics included: patients’ attitude towards remote care, participating in decentralized clinical trials, and preferences for and concerns with digital technology use. Results In total, 332 patients with MND participated. A majority of patients indicated they would be happy to self-monitor their health from home (69%), be remotely monitored by a multidisciplinary care team (75%), and would be willing to participate in clinical trials from home (65%). Patients considered respiratory function and muscle strength most valuable for home-monitoring. The majority of patients considered the use of at least three devices/apps (75%) once a week (61%) to be acceptable for home-monitoring. Fifteen percent of patients indicated they would not wish to perform home-measurements; reporting concerns about the burden and distress of home-monitoring, privacy and data security. Conclusion Most patients with MND exhibited a positive attitude toward the use of digital technology in both care and clinical trial settings. A subgroup of patients reported concerns with home-monitoring, which should be addressed in order to improve widespread adoption of remote digital technology in clinical MND care